PDS Biotechnology Corp — Form 8-K
Filed October 20, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
In September 2026, PDS Biotechnology completed a financing led by Nant Capital and appointed Dr. Patrick Soon-Shiong to its Board of Directors. Dr. Soon-Shiong brings prior experience obtaining FDA approval for an immunocytokine. The company is advancing PDS0301 (tumor-targeted IL-12) toward Phase 3 registration in metastatic colorectal cancer with liver metastases, which showed a 71.4% response rate and ~80% 24-month survival in Phase 2. The company also holds PDS0101 (Versamune HPV16 cancer vaccine), which demonstrated a 39.3-month median overall survival in combination with pembrolizumab in HPV16-positive head and neck cancer and carries FDA Fast Track designation for VERSATILE-003.
Why this rating
Financing + credible oncology board member validates approach; PDS0301 Phase 2 data compelling for ~$60M company. Meaningful but early-stage—Phase 3 still in design, PDS0101 seeking partner.
See more from October 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.